For research use only. Not for therapeutic Use.
FH535(CAT: I000367) is a small molecule inhibitor that targets the Wnt/β-catenin signaling pathway. It was first identified as a compound that selectively induces apoptosis in cancer cells expressing wild-type p53 but not in cells with mutant p53. Further studies revealed that FH535 can inhibit the interaction between β-catenin and Tcf/Lef, which results in the downregulation of β-catenin target genes. FH535 has been shown to have anticancer effects in various types of cancer cells, including colon cancer, breast cancer, and hepatocellular carcinoma. In addition to its anticancer effects, FH535 has also been investigated for its potential in regenerative medicine, as it has been shown to promote cardiomyocyte differentiation and enhance neuronal differentiation of embryonic stem cells.
| Catalog Number | I000367 |
| CAS Number | 108409-83-2 |
| Synonyms | 2,5-dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide |
| Molecular Formula | C₁₃H₁₀Cl₂N₂O₄S |
| Purity | ≥95% |
| Target | Wnt/β-catenin |
| Solubility | DMSO: ＞ 10 mM |
| Storage | Store at -20°C |
| IC50 | 1.1 uM (Cytotoxicity in the CCLP-1 cell line) |
| IUPAC Name | 2,5-dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide |
| InChI | InChI=1S/C13H10Cl2N2O4S/c1-8-6-10(17(18)19)3-5-12(8)16-22(20,21)13-7-9(14)2-4-11(13)15/h2-7,16H,1H3 |
| InChIKey | AXNUEXXEQGQWPA-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C2=C(C=CC(=C2)Cl)Cl |
